{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T09:04:00Z","timestamp":1745831040464},"reference-count":10,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.8377-16","type":"journal-article","created":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T22:13:48Z","timestamp":1501539228000},"page":"2229-2232","source":"Crossref","is-referenced-by-count":6,"title":["Severe Thrombocytopenia During Dolutegravir-containing Antiretroviral Therapy"],"prefix":"10.2169","volume":"56","author":[{"given":"Kazuhiko","family":"Nakaharai","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Infection Control, Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Miyajima","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Infection Control, Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Infection Control, Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Infection Control, Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Hosaka","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Infection Control, Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Horino","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Infection Control, Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Infection Control, Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Kandel CE, Walmsley SL. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Devel Ther 9: 3547-3555, 2015."},{"key":"2","unstructured":"2. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009."},{"key":"3","unstructured":"3. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 369: 1807-1818, 2013."},{"key":"4","unstructured":"4. van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S\/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. LnID 12: 111-118, 2012."},{"key":"5","unstructured":"5. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. LnID 13: 927-935, 2013."},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382: 700-708, 2013.","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"7","unstructured":"7. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 383: 2222-2231, 2014."},{"key":"8","unstructured":"8. Arnold DM, Nazi I, Warkentin TE, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev 27: 137-145, 2013."},{"key":"9","unstructured":"9. Danziger-Isakov L, Mark Baillie G. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin Transplant 23: 295-304, 2009."},{"key":"10","unstructured":"10. Jabs DA, Ahuja A, Van Natta M, Dunn JP, Yeh S. Complications of AIDS Research Group: Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 120: 1262-1270, 2013."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/16\/56_8377-16\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T04:51:33Z","timestamp":1503118293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/16\/56_8377-16\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":10,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8377-16","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}